AUTHORS
Tejaswini Kuthuru, MS, Xiaojuan Cao2, Maggie Cox3, Stephen Oh, MD, PhD4, Grant Challen, PhD5, Andrew Lee Young, MD, PhD6
AFFILIATIONS
1 Washington University, Saint Louis, Missouri, United States
2 Washington University, Saint Louis, Missouri, United States
3 Washington University, Saint Louis, Missouri, United States
4 Washington University, Saint Louis, Missouri, United States
5 Washington University, Saint Louis, Missouri, United States
6 Washington University, Saint Louis, Missouri, United States
ABSTRACT
Myeloproliferative neoplasms (MPNs) are hematologic malignancies marked by the overproduction of myeloid cells and are diagnosed in 20,000 individuals yearly in the United States. The disease course is variable; some patients have few complications and stable disease over decades, while others progress to an aggressive and difficult to treat secondary acute myeloid leukemia (sAML). Progression varies by disease subtype; 5% of polycythemia vera (PV) and essential thrombocythemia (ET) patients progress to sAML, while up to 20% of primary myelofibrosis (pMF) patients progress to sAML. There is pressing need to better understand the process of sAML development to better predict who will develop this complication and may benefit from early therapeutic intervention.
The prevailing dogma is that sAML arises when the primary MPN clone acquires additional cooperating leukemogenic mutations. This is based on the observation that MPNs are largely driven by JAK2 V617F, CALR, and MPL mutations that are frequently detected at sAML diagnosis. Interestingly, sporadic case reports have identified individuals with JAK2 mutated MPN who later develop sAML lacking the MPN-initiating JAK2 mutation. Two potential hypotheses explain this observation: 1) during leukemic transformation, the JAK2 mutation has a disadvantage, leading to selective pressure to revert back to wild-type JAK2; or 2) the sAML arises in parallel to the MPN from an independent clone driven by different somatic mutations. Resolving this distinction is critical because if a subset of sAML cases represents de novo AML arising alongside an MPN, their natural history, prognosis, and therapeutic vulnerabilities may fundamentally differ.
To test these hypotheses, we performed targeted single-cell DNA sequencing and immunophenotyping to characterize the clonal organization in 30 patients with sAML arising after a JAK2 V617F mutated MPN. This approach used a 29-gene panel targeting genes recurrently mutated in leukemia and a CITE-seq antibody panel targeting 42 hematopoietic surface antigens. To our surprise, in 8/30 (27%) of cases the dominant sAML clone at diagnosis no longer contained the MPN-associated JAK2 mutation, which was either no longer present in the bone marrow (n=4) or present but in clonally distinct populations of cells (n=4). For example, one individual’s sAML contained a hotspot MPL W515L mutation—the causative mutation in 5% of ET cases—and an SF3B1 H662Q mutation, which had replaced the patient’s prior JAK2 V617F mutated MPN clone. In sAML cases which retained the JAK2 mutation, common cooperating mutations were in TP53, RUNX1, ASXL1, TET2, IDH1/2, and spliceosome genes. In sAML cases which lost the JAK2 mutation, common cooperating mutations were in TP53, RUNX1, DNMT3A, MPL, KRAS/NRAS, and spliceosome genes. We identified heterogeneity in surface immunophenotype within several sAML clones—different populations of genotypically similar cells displayed differences in cell surface markers within the same sample.
Together these findings provide primary patient data demonstrating that potentially up to a quarter of AML cases arising in the background of a JAK2 mutated MPN are clonally distinct and likely represent the development of a parallel de novo AML clone that is not secondary to the MPN. This evidence supports a unique model of tumorigenesis whereby one malignant clone potentially drives the development of a separate, clonally distinct malignancy. These findings have implications diagnostically as bulk sequencing will miss this clonal architecture and a JAK2 V617F mutation detected at sAML diagnosis may in fact represent the non-AML background MPN cells present at leukemic transformation. Our immunophenotyping findings suggest that surface marker heterogeneity can exist within the sAML clone, which has implications for flow cytometry-based measurable residual disease detection that targets a single leukemia-associated immunophenotype. Long-term, our goal is to leverage these findings to predict which MPN patients are at risk for sAML transformation, improve therapies to prevent sAML and identify differences in therapeutic vulnerability based on the mechanism of leukemic transformation.
DISCLOSURES
Tejaswini Kuthuru, MS: No relevant conflicts of interest to declare.